Lotus Pharmaceutical (“Lotus”) and Alvogen today announced the launch of the first generic equivalent of RevlimidTM (lenalidomide) in some of their CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and will be launched globally from 2019 onwards. It is a fully generic and bioequivalent version of RevlimidTM capsules and has been fully developed in-house at Lotus to be marketed globally.
Petar Vazharov, General Manager of Lotus and Executive Vice President at Alvogen in the APAC region, commented: “We are extremely proud to announce the launch of Lenalidomide. This product represents an outstanding milestone in the evolving portfolio at our Lotus Nantou plant. Being the first company to overcome development and manufacturing barriers and getting first approval in regulated markets further paves us the road to become a differentiated entity in the research and development of complex oncology medicines.”
Hacho Hatchikian, Executive Vice President at Alvogen in the CEE regions, added: “Lenalidomide launch is a major landmark for Alvogen as we successfully became the first generic company to launch the generic of RevlimidTM in our major markets. Patients now finally will have access to an affordable and high-quality treatment for the various devastating oncology indications the product is targeted at. Having Lenalidomide in our portfolio also enhances our drive to be key oncology player in the CEE region.”
RevlimidTM is indicated for the treatment of various oncology diseases including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. By the time of Alvogen launch, RevlimidTM is perceived as the single biggest-selling oncology drug with approximately $9.8 billion sales globally. Lotus currently has more than 10 oncology products in development and pending approval globally.